NDAORALTABLETPriority Review
Approved
Aug 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
SELZENTRY (maraviroc) by GSK is chemokine co-receptor 5 antagonists [moa]. First approved in 2007.
Drug data last refreshed 2d ago
Mechanism of Action
Chemokine Co-receptor 5 Antagonists
Pharmacologic Class:
CCR5 Co-receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke
Started Sep 2022
120 enrolled
Stroke
Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).
Started Jun 2020
60 enrolled
COVID-19
Maraviroc to Augment Rehabilitation Outcomes After Stroke
Started Aug 2019
2 enrolled
Stroke
Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection
Started Jun 2017
47 enrolled
HIV Infections
Maraviroc Efficacy for Hepatitis C
Started Jun 2017
10 enrolled
Hepatitis CHuman Immunodeficiency Virus
Worked on SELZENTRY at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.